MDS News
Here is the latest news related to MDS:
Treatment with treosulfan and fludarabine was effective and caused few negative side effects in myelodysplastic syndromes patients receiving donor stem cell transplants, according to a recent clinical trial conducted by researchers in Washington and Oregon.
By the end of the trial, all surviving patients successfully achieved complete engraftment of the donor stem cells, meaning that the donor stem cells began producing healthy blood cells and none of the patient’s stem cells remained. Overall, the treatment was particularly effective in patients categorized as low- or standard-risk based on their genetics.
Only…
This article is part of a series about stem cell transplantation in MDS, which will be published over the next couple of weeks. The series will explain the different types of stem cell transplants, describe the procedure for both patient and donor, address benefits and risks, and report on experiences of MDS patients who underwent the procedure.
In this final part of the series, MDS patients who underwent a donor stem cell transplantation share their experiences with the procedure and how it impacted their life after the transplant.
This article…
A recent study of myelodysplastic syndromes patients who received a donor stem cell transplant showed that the percentage of donor versus patient stem cells in the bone marrow or blood may be able to predict relapse.
Stem cell transplants for myelodysplastic syndromes (MDS) patients are usually performed by giving the patient stem cells from a healthy donor. This is the only known cure for MDS.
Ideally, the patient’s blood-forming stem cells are destroyed and replaced by the donor’s healthy stem cells. The donor’s cells then grow in the patient and…
Revlimid Receives Approval In Japan For Treatment Of Del-5q MDS – On Friday, Celgene announced that Japan’s Ministry of Health, Labour and Welfare, the agency that is responsible for the regulation of pharmaceuticals and medical devices in Japan, approved Revlimid (lenalidomide) for the treatment of MDS associated with a deletion 5q chromosomal abnormality. The approval was based on the efficacy and safety demonstrated during several international clinical trials. In the U.S., the approved use of Revlimid also requires that del-5q MDS patients be dependent on red blood cell transfusions. For more information, please see the Celgene press release.
Conference For MDS Patients And Their Families – The MDS Foundation is sponsoring a one-day conference for patients with MDS and their families on September 9 at the Hilton University of Florida Conference Center in Gainsville. Dr. Christopher Cogle, an MDS specialist from Shands Hospital at the University of Florida, will speak about the latest on the diagnosis and treatment of MDS. The event will begin at 9 a.m. and conclude at 2 p.m. It will include breakfast and lunch and is free to attend. Registration is required. For more information or to register, please see the MDS Foundation website.
For a more detailed listing of MDS related events, please check the MDS Beacon Events Calendar.
This article is part of a series about stem cell transplantation in MDS, which will be published over the next couple of weeks. The series will explain the different types of stem cell transplants, describe the procedure for both patient and donor, address benefits and risks, and talk about prognosis and life after the transplant.
Although stem cell transplants can cure MDS, they are associated with certain risks and complications.
This article will summarize the benefits and risks associated with the procedure.
Benefits
A stem cell transplant replaces an MDS…